A Study of PRT2527 in Participants With Relapsed/Refractory Hematologic Malignancies
NCT05665530
Description of the Study
This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate the safety, tolerability, recommended phase 2 dose (PR2D), and preliminary efficacy of PRT2527 as a monotherapy and in combination with zanubrutinib.
Eligibility:
Age18+
Sex All
StatusRecruiting